邹军辉 万晓春 王蒲.EB 病毒疫苗的研究进展[J].现代生物医学进展英文版,2015,15(3):543-546. |
EB 病毒疫苗的研究进展 |
New Progress on Epstein-Barr Virus Vaccine Research |
|
DOI: |
中文关键词: EB 病毒 疫苗 预防 治疗 |
英文关键词: EBV Vaccine Prevention Therapy |
基金项目:深圳市知识创新计划基础研究项目(SY39410) |
|
Hits: 1810 |
Download times: 4476 |
中文摘要: |
:EB病毒是一种感染最广泛的人类酌疱疹病毒,与传染性单核细胞增多症、鼻咽癌、Hodgkin’s 淋巴瘤以及Burkitt 淋巴瘤等
发生密切相关。预防和治疗EB病毒相关疾病一直是研究的热点,预防性疫苗主要以病毒包膜糖蛋白gp350 为靶点,刺激机体产
生抗体以阻止病毒感染;已有多种疫苗进入临床试验,用于预防传染性单核细胞增多症和器官移植后淋巴增殖性紊乱等疾病,并
取得良好的试验结果。治疗性疫苗则以病毒复制感染过程中表达的病毒核抗原(EBNAs)和潜伏膜蛋白(LMP1 和LMP2)为免疫
治疗靶点,刺激机体产生特异性细胞免疫应答,增强细胞毒性T细胞杀伤肿瘤作用。国内外均已有疫苗进入针对鼻咽癌等肿瘤免
疫治疗的临床试验,试验结果表明疫苗兼具良好的安全性和免疫原性。本文还综述EB病毒疫苗研究的最新方法、策略和成果,并
探讨其中可借鉴的技术和思路,为EB病毒疫苗的研究提供潜在可行的新途径。 |
英文摘要: |
Epstein-Barr virus (EBV) is a human gamma herpes virus, infecting the most widespread of humans that has been
linked to various lymphoid and epithelial cell malignancies, such as infectious mononucleosis (IM), nasopharyngeal carcinoma (NPC),
Hodgkin’s lymphoma and Burkitt lymphoma. Prevention and treatment of diseases related to EBV has been a hot research topic. The
viral envelope glycoprotein gp350 that elicits neutralizing antibodies to prevent virus infection is a major target for preventive vaccine
development. The clinical trials have demonstrated that IM and posttransplantation lymphoproliferative disorders (PTLD) could be
effectively prevented by the vaccines. EBV nuclear antigens (EBNAs), latent membrane proteins 1 and 2 (LMP1 and LMP2) are
immunotherapy targets that induce specific cellular immune response, enhance specific cytotoxic T lymphocyte responses and confer
antitumor immunity. Immunotherapy vaccine trials for NPC have been performed in China and abroad and the results demonstrated that
the vaccines have good safety and immunogenicity. In this paper, the newest merits of vaccines for EBV were summarized and the
strategies and challenges for future EBV vaccine research and development were also discussed. |
View Full Text
View/Add Comment Download reader |
Close |